Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Enferm Infecc Microbiol Clin (Engl Ed) ; 41(10): 621-624, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36737371

RESUMEN

INTRODUCTION: Ceftolozane/tazobactam has shown excellent activity against Pseudomonas aeruginosa, but this drug is not always included in commercial panels. The aim of the study was to evaluate the performance of 2 gradient strips (BioMérieux and Liofilchem) and a commercial microdilution panel (Sensititre, EURGNCOL panel) using this combination against carbapenem-resistant P. aeruginosa isolates. METHODS: Three commercial methods were tested with 41 metallo-beta-lactamase-producing and 59 non-carbapenemase-producing P. aeruginosa isolates. Broth microdilution was used as reference. RESULTS: All carbapenemase-producing isolates and only one non-producing isolate were resistant to this antibiotic. Both essential agreement and bias were outside the acceptance intervals since MIC values were higher than reference values for all three methods. The Kappa index indicated poor or weak agreement. Changes in clinical categories were observed in 3 isolates. CONCLUSIONS: The three methods yielded poor agreement with the reference. Despite the differences in MIC values, fewer than 3% involved category changes.


Asunto(s)
Infección Hospitalaria , Infecciones por Pseudomonas , Humanos , Pseudomonas aeruginosa , Infecciones por Pseudomonas/tratamiento farmacológico , Infección Hospitalaria/tratamiento farmacológico , Tazobactam/farmacología , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Carbapenémicos/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA